Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. Part II: Furoxan derivatives

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7583-7592

  Dos Santos, Jean Leandro ^a   Lanaro, Carolina ^b   Chelucci, Rafael Consolin ^a   Gambero, Sheley ^b   Bosquesi, Priscila Longhin ^a   Reis, Juliana Santana ^a   Lima, Lídia Moreira ^c   Cerecetto, Hugo ^d   González, Mercedes ^d   Costa, Fernando Ferreira ^b   Chung, Man Chin ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[[2 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL) 2 HYDROXYBENZOYL]OXY]METHYL] 2 N OXIDE 4 PHENYL 1,2,5 OXADIAZOLE; 3 [[[2 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)BENZOYL]OXY]METHYL] 2 HYDROXY 4 PHENYL 2 N OXIDE 1,2,5 OXADIAZOLE; 3 [[[3 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)BENZOYL]OXY]METHYL] 2 N OXIDEO 4 PHENYL 1,2,5 OXADIAZOLE; 4 [2 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL N PHENYLBENZENOCARBOXAMIDE)ETHOXY] 3 (PHENYLSULFONYL) 2 N 1,2,5 OXADIAZOLE; 4 [2 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL N PHENYLBENZENOSULFONAMIDE)ETHOXY] 3 (PHENYLSULFONYL) 2 N 1,2,5 OXADIAZOLE; 4 [2 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)ETHOXY] 3 (PHENYLSULFONYL) 2 N 1,2,5 OXADIAZOLE; ANTISICKLING AGENT; CYCLOPHOSPHAMIDE; DIPYRONE; FUROXAN DERIVATIVE; GAMMA GLOBIN; HYDROXYUREA; NITRITE; PHTHALIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUTAGENESIS; NONHUMAN; PROTEIN EXPRESSION; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NITRIC OXIDE DONORS; OXADIAZOLES; POLYMERASE CHAIN REACTION;

EID: 84866331785     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300602n     Document Type: Article

References (58)

1. Cyrklaff, M.; Sanchez, C. P.; Kilian, N.; Bisseye, C.; Simpore, J.; Frischknecht, F.; Lanzer, M. Hemoglobins S and C interfere with action remodeling in Plasmodium falciparum -infected erythrocytes Science 2011, 334 (6060) 1283-1286
2. Stuart, M. J.; Nagel, R. L. Sickle-cell disease Lancet 2004, 364, 1343-1360 (Pubitemid 39335827)
3. Hoppe, C. C. Novel therapies targeting the endothelium in sickle cell disease Hemoglobin 2011, 35 (5-6) 530-546
4. Hebbel, R. P.; Yamada, O.; Moldow, C. F.; Jacob, H. S.; White, J. G.; Eaton, J. W. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible merchanism for microvascular occlusion in sickle cell disease J. Clin. Invest. 1980, 65, 154-160 (Pubitemid 10214342)
5. Dos Santos, J. L.; Chin, C. M. Recent insights on the medicinal chemistry of sickle cell disease Curr. Med. Chem. 2011, 18 (15) 2339-2358
6. Lanaro, C.; Franco-Penteado, C. F.; Albuqueque, D. M.; Saad, S. T.; Conran, N.; Costa, F. F. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy J. Leukocyte Biol. 2009, 85 (2) 253-242
7. Okpala, I. Leukocyte adhesion and the pathophysiology of sickle cell disease Curr. Opin. Hematol. 2006, 13, 40-44
8. Miller, S. T.; Kim, H. Y.; Weiner, D.; Wager, C. G.; Gallagher, D.; Styles, L.; Dampier, C. D. Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN). Inpatient management of sickle cell pain: a "snapshot" of current practice Am. J. Hematol. 2012, 87 (3) 333-336
9. Platt, O. S.; Thorington, B. D.; Brambilla, D. J.; Milner, P. F.; Rosse, W. F.; Vichinsky, E.; Kinney, T. R. Pain in sickle cell disease. Rates and risk factors N. Engl. J. Med. 1991, 325 (1) 11-16
10. Yusuf, H. R.; Atrash, H. K.; Grosse, S. D.; Parker, C. S.; Grant, A. M. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007 Am. J. Prev. Med. 2010, 38 (4) S536-S541
11. Graido-Gonzalez, E.; Doherty, J. C.; Bergreen, E. W.; Telfer, M.; McMillen, M. A. Plasma endothelin-1, cytokine and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis Blood 1998, 92 (7) 2551-2555 (Pubitemid 28453000)
12. Tomer, A.; Harker, L. A.; Kasey, S.; Eckman, J. R. Thrombogenesis in sickle cell disease J. Lab. Clin. Med. 2001, 137 (6) 398-407 (Pubitemid 32473618)
13. Charache, S.; Barton, F. B.; Moore, R. D.; Terrin, M. L.; Steinberg, M. H.; Dover, G. J.; Ballas, S. K.; McMahon, R. P.; Castro, O.; Orringer, E. P. Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive "switching" agent: the multicenter study of hydroxyurea in sickle cell anemia Medicine 1996, 75 (6) 300-325
14. Hankins, J.; Aygun, B. Pharmacotherapy in sickle cell disease-state of the art and future prospects Br. J. Hamaetol. 2009, 145 (3) 296-308
15. Santos, J. L.; Lanaro, C.; Chin, C. M. Advances in sickle cell disease treatment: from drug discovery until the patient monitoring Cardiovasc. Hematol. Agents Med. Chem. 2011, 9 (2) 113-127
16. Laurance, S.; Pellay, F. X.; Dossou-Yovo, O. P.; Verger, E.; Krishnamoorthy, R.; Lapoumeroulie, C.; Benecke, A.; Elion, J. Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell disease Pharmacogenet. Genomics 2010, 20 (4) 257-268
17. Santos, J. L.; Bosquesi, P. L.; Almeida, A. E.; Chung, M. C.; Varanda, E. A. Mutagenic and Genotoxic Effect of Hydroxyurea Int. J. Biomed. Sci. 2011, 16, 2982-2989
18. Valfar, H.; Valfar, F.; Darvill, A.; Albersheim, P.; Kutlar, A.; Woods, K. F.; Hardin, J. Predicting the effectiveness of hydroxyurea in individual sickle cell anemia patients Artif. Intell. Med. 2000, 18 (2) 133-148 (Pubitemid 30050743)
19. Aerbajinai, W.; Zhu, J.; Gao, Z.; Chin, K.; Rodgers, G. P. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis Blood 2007, 110, 2864-2871 (Pubitemid 350006939)
20. Moutouh-de-Parseval, L. A.; Verhelle, D.; Glezer, E.; Jensen-Pergakes, K.; Ferguson, G. D.; Corral, L. G.; Morris, C. L.; Muller, G.; Brady, H.; Chan, K. Pomalidomide and lenalidomide regulated erythropoiesis and fetal hemoglobin production in human CD34+ cells J. Clin. Invest. 2008, 118, 248-258
21. Kutlar, A.; Meiler, S.; Swerdlow, P.; Knight, R. Thalidomide and its analogs for hemoglobinopathies: two birds with one stone? Expert Rev. Hematol. 2012, 5 (1) 9-11
22. Ribeiro, R. A; Vale, M. L.; Ferreira, S. H.; Cunha, F. Q. Analgesic effect of thalidomide on inflammatory pain Eur. J. Pharmacol. 2000, 391, 97-103 (Pubitemid 30138085)
23. Xu, Y.; Li, J.; Ferguson, G. D.; Mercurio, F.; Khambatta, G.; Morrison, L.; Lopez-Girona, A.; Corral, L. G.; Webb, D. R.; Bennett, B. L.; Xie, W. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases Blood 2009, 114 (2) 338-345
24. Dos Santos, J. L.; Lanaro, C.; Lima, L. M.; Gambero, S.; Franco-Penteado, C. F.; Alexandre-Moreira, M. S.; Wade, M.; Yerigenahally, S.; Kutlar, A.; Meiler, S. E.; Costa, F. F.; Chung, M. C. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms J. Med. Chem. 2011, 54 (16) 5811-5819
25. Cerecetto, H.; Porcal, W. Pharmacological properties of furoxans and benzofuroxans: recent developments Mini-Rev. Med. Chem. 2005, 5 (1) 57-71 (Pubitemid 40136481)
26. Scatena, R.; Bottoni, P.; Pontoglio, A.; Giardina, B. Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks Curr. Med. Chem. 2010, 17, 61-73
27. Cerecetto, H.; Dias, E.; Di Maio, R.; González, M.; Pacce, S.; Saenz, P.; Seoane, G.; Suescun, L.; Mombrú, A.; Fernández, G.; Lema, M.; Villalba, J. Synthesis and herbicidal activity of N- oxide derivatives J. Agric. Food Chem. 2000, 48, 2995-3002 (Pubitemid 30490527)
28. Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; Di Stilo, A.; Galli, U.; Gasco, A. Water Soluble Furoxan Derivatives as NO Prodrugs. J. Med. Chem. 1997, 40, 463-469; 2288. (Pubitemid 27080025)
29. Gasco, A.; Mortarini, V.; Rua, G.; Serafino, A. Unsymmetrically substituted furoxans. III. Methylnitrofuroxan: Its structure and behaviour toward nucleophilic substitution J. Heterocycl. Chem. 1973, 10, 587-590
30. Gasco, A.; Boulton, A. J. Furazans and furazan oxides. Part IV. The structures and tautomerism of some unsymmetrically substituted furoxans J. Chem. Soc., Perkin Trans. 2 1973, 1613-1617
31. Ovchinnikov, I. V.; Strelenko, Y. A.; Popov, N. A.; Finogenov, A. O.; Makhova, N. N. A study of the reaction mechanism of 3-nitro-4- R -furoxans formation by nitrosation of dipotassium salts of 1-hydroxyimino-2,2-dinitro-1- R -ethanes Russ. Chem. Bull. 2011, 60 (5) 855-860
32. Tsikas, D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the l -arginine/nitric oxide area of research J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2007, 851, 51-70 (Pubitemid 46720134)
33. Collier, H. O. J.; Dinneen, L. C.; Johnson, C. A.; Schneider, C. The abdominal constriction response and its suppression by analgesic drugs in the mouse Br. J. Pharmacol. 1968, 32, 285-291
34. Hayashi, M.; Morita, T.; Kodama, Y.; Sofuni, T.; Ishidate, M. J. The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange-coated slides Mutat. Res. 1990, 245, 245-249
35. Cartron, J. P.; Elion, J. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea Transfus. Clin. Biol. 2008, 15, 39-50
36. Lou, T. F.; Singh, M.; Mackie, A.; Li, W.; Pace, B. S. Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation Exp. Biol. Med. 2009, 234, 1374-1382
37. Santos, J. L.; Varanda, E. A.; Lima, L. M.; Chung, M. C. Mutagenicity of new lead compounds to treat sickle cell disease symptoms in Salmonella/microsome assay Int. J. Mol. Sci. 2010, 11, 779-788
38. Santos, J. L.; Bosquesi, P. L.; Varanda, E. A.; Lima, L. M.; Chung, M. C. Assessment of the in vivo genotoxicity of new lead compounds to treat sickle cell disease Molecules 2011, 16, 2982-2989
39. Meiler, S. E.; Wade, M.; Kutlar, F.; Yerigenahally, S. D.; Xue, Y.; Moutouh-de Parseval, L. A.; Corral, L. G.; Swerdlow, P. S.; Kutlar, A. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice Blood 2011, 118 (4) 1109-1112
40. Morris, C. R.; Gladwin, M. T.; Kato, G. J. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders Curr. Mol. Med. 2008, 8 (7) 620-632
41. Mack, A. K.; McGowan, I. V. R.; Tremonti, C. K.; Ackah, D.; Barnett, C.; Machado, R. F.; Gladwin, M. T.; Kato, G. J. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study Br. J. Hamaetol. 2008, 142 (6) 971-978
42. Kaul, D. K.; Zhang, X.; Dasgupta, T.; Fabry, M. E. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress Am. J. Physiol.: Heart Circ. Physiol. 2008, 295 (1) H39-H47
43. Head, C. A.; Swerdlow, P.; McDade, W. A.; Joshi, R. M.; Ikuta, T.; Cooper, M. L.; Eckman, J. R. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis Am. J. Hematol. 2010, 85 (10) 800-802
44. Gladwin, M. T.; Kato, G. J.; Weiner, D.; Onyekwere, O. C.; Dampier, C.; Hsu, L.; Hagar, R. W.; Howard, T.; Nuss, R.; Okam, M. M.; Tremonti, C. K.; Berman, B.; Villella, A.; Krishnamurti, L.; Lanzkron, S.; Castro, O.; Gordeuk, V. R.; Coles, W. A.; Peters-Lawrence, M.; Nichols, J.; Hall, M. K.; Hildesheim, M.; Blackwelder, W. C.; Baldassarre, J.; Casella, J. F. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial JAMA, J. Am. Med. Assoc. 2011, 305 (9) 893-902
45. Canalli, A. A.; Franco-Penteado, C. F.; Saad, S. T.; Conran, N.; Costa, F. F. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation Haematologica 2008, 93 (4) 605-609 (Pubitemid 351536391)
46. Cokic, V. P.; Smith, R. D.; Beleslin-Cokic, B. B.; Njoroge, J. M.; Miller, J. L.; Gladwin, M. T.; Schechter, A. N. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase J. Clin. Invest. 2003, 111 (2) 231-239 (Pubitemid 36105922)
47. Vandy Black, L.; Smith, W. R. Evidence-based mini-review: Are systemic corticosteroids an effective treatment for acute pain in sickle cell disease? Hematology Am. Soc. Hematol. Educ. Program 2010, 416-417
48. Ribeiro, R. A; Vale, M. L.; Ferreira, S. H.; Cunha, F. Q. Analgesic effect of thalidomide on inflammatory pain Eur. J. Pharmacol. 2000, 391, 97-103 (Pubitemid 30138085)
49. Conran, N.; Oresco-Santos, C.; Acosta, H. C.; Fattori, A.; Saad, S. T.; Costa, F. F. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients Br. J. Hamaetol. 2004, 124, 547-554 (Pubitemid 38230601)
50. Burney, S.; Caulfield, J.; Niles, J.; Wishnok, J.; Tannenbaum, S. The chemistry of DNA damage from nitric oxide and peroxynitrite Mutat. Res. 1999, 424, 37-49 (Pubitemid 29101606)
51. Felley-Bosco, E. Role of nitric oxide in genotoxicity: Implication for carcinogenesis Cancer Metastasis Rev. 1998, 17, 25-37 (Pubitemid 28194644)
52. Balbo, S.; Lazzarato, L.; Di Stilo, A.; Fruttero, R.; Lombaert, N.; Kirsch-Volders, M. Studies of the potential genotoxic effects of furoxans: the case of CAS 1609 and of the water-soluble analogue of CHF 2363 Toxicol. Lett. 2008, 178, 44-51
53. Cabrera, M.; López, G. V.; Gómez, L. E.; Breijo, M.; Pintos, C.; Botti, H.; Raymondo, S.; Vettorazzi, A.; Ceráin, A. L.; Monge, A.; Rubbo, H.; González, M.; Cerecetto, H. Genetic toxicology and preliminary in vivo studies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents Drug Chem. Toxicol. 2011, 34, 285-293
54. Machado, A. L.; Lima, L. M.; Araújo, J. X.; Fraga, C. A.; Koatz, V. L.; Barreiro, E. J. Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide Bioorg. Med. Chem. Lett. 2005, 15 (4) 1169-1172 (Pubitemid 40467439)
55. Cerecetto, H.; Di Maio, R.; Ibarruri, G.; Seoane, G.; Denicola, A.; Peluffo, G.; Quijano, C.; Paulino, M. Synthesis and Antitrypanosomal Activity of Novel 5-Nitro-2-furaldehyde and 5-Nitrothiophene-2-carboxaldehyde Semicarbazone Derivatives Farmaco 1998, 53 (2) 89-94 (Pubitemid 29101300)
56. Cerecetto, H; Di Maio, R; González, M; Risso, M; Saenz, P; Seoane, G; Denicola, A; Peluffo, G; Quijano, C; Olea-Azar, C. 1,2,5-Oxadiazole N- oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships J. Med. Chem. 1999, 42, 1941-1950 (Pubitemid 29269627)
57. López, G. V.; Batthyány, C.; Blanco, F.; Botti, H.; Trostchansky, A.; Migliaro, E.; Radi, R.; González, M.; Cerecetto, H.; Rubbo, H. Design, synthesis, and biological characterization of potential antiatherogenic nitric oxide releasing tocopherol analogs Bioorg. Med. Chem. 2005, 13, 5787-5796 (Pubitemid 41247761)
58. Vandesompele, J.; De Preter, K.; Pattyn, F.; Poppe, B.; Van Roy, N.; De Paepe, A.; Speleman, F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol. 2002, 3 (7) research0034.1-research0034.11